Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 16/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.62 |
| ▸ | CCL5 | P13501 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5775608 | 0.91 | KCNH2 (0.64) | CCR5KCNH2CYP3A4CYP2D6 | |
| SCHEMBL5775633 | 0.90 | CCR5 (0.51) | CCR5KCNH2 | |
| SCHEMBL5949989 | 0.85 | CCR5 (0.49) | CCR5KCNH2CYP3A4CYP2D6 | |
| SCHEMBL5949993 | 0.79 | CCR5 (0.43) | CCR5KCNH2CYP3A4CYP2D6 | |
| SCHEMBL3639322 | 0.79 | CCR5 (0.46) | CCR5KCNH2 | |
| SCHEMBL3635731 | 0.78 | CA1 (0.51) | CCR5 | |
| SCHEMBL3634919 | 0.77 | CA1 (0.51) | — | |
| SCHEMBL13930621 | 0.76 | CA1 (0.49) | CCR5 | |
| SCHEMBL6011793 | 0.76 | CCR5 (0.55) | CCR5KCNH2CCL5 | |
| SCHEMBL6011790 | 0.76 | CCR5 (0.55) | CCR5KCNH2CCL5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1572683-B1 | NOVEL PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR CCR5 | ASTRAZENECA AB (SE) | 2006-10-18 | — | — | EP | disclosed |
| US-20060069120-A1 | Novel piperidine derivaties as modulators of chemokine receptor ccr5 | ASTRAZENECA AB (SE) | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069120-A1 | Novel piperidine derivaties as modulators of chemokine receptor ccr5 | CCR5, CCR2, CXCR4 | CCR5 1/4885KCNH2 1959/4885CCL5 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.